Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effects of drugs influencing monoamine mechanisms on the increase in brain dopamine produced by axotomy or treatment with gammahydroxybutyric acid.

× No keyword cloud information.

16 in total

1. Early and selective increase in brain dopamine levels after axotomy.

Authors: N E Andén; P Bédard; K Fuxe; U Ungerstedt
Journal: Experientia Date: 1972-03-15

2. Importance of nervous impulse flow for the neuroleptic induced increase in amine turnover in central dopamine neurons.

Authors: N E Andén; H Corrodi; K Fuxe; U Ungerstedt
Journal: Eur J Pharmacol Date: 1971-07 Impact factor: 4.432

3. The inhibition of catecholamine biosynthesis by apomorphine.

Authors: M Goldstein; L S Freedman; T Backstrom
Journal: J Pharm Pharmacol Date: 1970-09 Impact factor: 3.765

4. Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity.

Authors: W Kehr; A Carlsson; M Lindqvist; T Magnusson; C Atack
Journal: J Pharm Pharmacol Date: 1972-09 Impact factor: 3.765

5. Evidence for dopamine receptor stimulation by apomorphine.

Authors: N E Andén; A Rubenson; K Fuxe; T Hökfelt
Journal: J Pharm Pharmacol Date: 1967-09 Impact factor: 3.765

6. Functional role of the nigro-neostriatal dopamine neurons.

Authors: N E Andén; A Dahlström; K Fuxe; K Larsson
Journal: Acta Pharmacol Toxicol (Copenh) Date: 1966

7. Application of steady-state kinetics to the study of catecholamine turnover after monoamine oxidase inhibition or reserpine administration.

Authors: N H Neff; E Costa
Journal: J Pharmacol Exp Ther Date: 1968-03 Impact factor: 4.030

Review 8. Effect of drugs on amines in the CNS.

Authors: F Sulser; E Sanders-Bush
Journal: Annu Rev Pharmacol Date: 1971 Impact factor: 13.820

9. End-product inhibition of tyrosine hydroxylase as a possible mechanism for regulation of norepinephrine synthesis.

Authors: S Spector; R Gordon; A Sjoerdsma; S Udenfriend
Journal: Mol Pharmacol Date: 1967-11 Impact factor: 4.436

10. The effect of sodium -hydroxybutyrate on the metabolism of dopamine in the brain.

Authors: D A Hutchins; K S Rayevsky; D F Sharman
Journal: Br J Pharmacol Date: 1972-11 Impact factor: 8.739

11 in total

Review 1. Effects of chronic neuroleptic treatment on dopamine release: insights from studies using 3-methoxytyramine.

Authors: M F Egan; S Chrapusta; F Karoum; B K Lipska; R J Wyatt
Journal: J Neural Transm (Vienna) Date: 1996 Impact factor: 3.575

2. On the interaction of 5-hydroxytryptophan and 5-hydroxytryptamine with dopamine metabolism in the rat striatum.

Authors: N Awazi; H C Guldberg
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1978-05 Impact factor: 3.000

3. Increase in brain dopamine after axotomy or treatment with gammahydroxybutyric acid due to elimination of the nerve impulse flow.

Authors: G Stock; T Magnusson; N E Andén
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1973 Impact factor: 3.000

4. Effects of morphine on central catecholamine turnover, blood pressure and heart rate in the rat.

Authors: C Gomes; T H Svensson; G Trolin
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1976-08 Impact factor: 3.000

5. Effect of (+) amphetamine on monoamine synthesis and metabolism after axotomy in rat forebrain.

Authors: W Speckenbach; W Kehr
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1976-12 Impact factor: 3.000

6. Demonstration of autoreceptors on dopamine neurons in different brain regions of rats treated with gammabutyrolactone.

Authors: N E Andén; M Grabowska-Andén; B Liljenberg
Journal: J Neural Transm Date: 1983 Impact factor: 3.575

Review 7. Interaction of haloperidol and gamma-butyrolactone with (+)-amphetamine-induced changes in monoamine synthesis and metabolism in rat brain.

Authors: W Kehr; W Speckenbach; R Zimmermann
Journal: J Neural Transm Date: 1977 Impact factor: 3.575

Effects of drugs influencing monoamine mechanisms on the increase in brain dopamine produced by axotomy or treatment with gammahydroxybutyric acid.